Seth Ginsberg 14:20 But a question back to you, Robert, I hear from people all the time that like they dont like vaccines because, essentially, they dont like vaccine makers or the drug companies, and the whole conversation quickly devolves into this trust issue with drug companies, like, how do we address that in a productive way
The decision should be made collaboratively with your healthcare provider based on your complete health picture, not based on A1C alone
At Meto, our Pre-GLP-1 Metabolic Panel is designed to give you: A complete picture of your metabolic health Insights into insulin resistance and inflammation Clinically actionable data to guide treatment Because better data leads to better outcomes
MASH affects around 14.9 million adults in the U.S., or roughly 6% of the population, and its prevalence is on the rise